
Novo Nordisk to replace CEO Lars Jorgensen amid stiff competition in obesity drug market; stock down 33% YTD
Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was stepping down by “mutual agreement” with the company’s board of directors, citing “recent market challenges” and a steep decline in the company’s share price. Lars Fruergaard Jorgensen’s departure comes a week after the company downgraded its sales…